Bevacizumab induces regression of vestibular schwannomas in patients with neurofibromatosis type 2

被引：101

作者：

Mautner, Victor-Felix ^{[1
]}

Nguyen, Rosa ^{[1
]}

Kutta, Hannes ^{[2
]}

Fuensterer, Carsten ^{[5
]}

Bokemeyer, Carsten ^{[4
]}

Hagel, Christian ^{[3
]}

Friedrich, Reinhard E. ^{[1
]}

Panse, Jens ^{[4
]}

机构：

[1] Univ Med Ctr Hamburg Eppendorf, Dept Maxillofacial Surg, D-20246 Hamburg, Germany

[2] Univ Med Ctr Hamburg Eppendorf, Dept Otolaryngol, D-20246 Hamburg, Germany

[3] Univ Med Ctr Hamburg Eppendorf, Inst Neuropathol, D-20246 Hamburg, Germany

[4] Univ Med Ctr Hamburg Eppendorf, Dept Hematol Oncol, Ctr Canc, D-20246 Hamburg, Germany

[5] MRI Inst, Hamburg Othmarschen, Germany

来源：

NEURO-ONCOLOGY | 2010年 / 12卷 / 01期

关键词：

bevacizumab; neurofibromatosis type 2; vestibular schwannoma; RECURRENCE; EFFICACY; PATTERNS; GLIOMAS;

D O I：

10.1093/neuonc/nop010

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Bilateral vestibular schwannomas are the hallmark of neurofibromatosis type 2 (NF2), and these tumors impair hearing and frequently lead to deafness. Neurosurgical intervention, the only established treatment, often damages the vestibular nerve. We report 2 cases in which treatment with bevacizumab (for 3 months in one case and 6 months in the other) induced regression of progressive vestibular schwannomas by more than 40% and substantially improved hearing in the patient treated for 6 months. Bevacizumab therapy may thus provide an effective treatment for progressive vestibular schwannomas in patients with NF2.

引用

页码：14 / 18

页数：5

共 9 条

[1] Malignant transformation and new primary tumours after therapeutic radiation for benign disease: substantial risks in certain tumour prone syndromes [J].

Evans, DGR ;

Birch, JM ;

Ramsden, RT ;

Sharif, S ;

Baser, ME .

JOURNAL OF MEDICAL GENETICS, 2006, 43 (04) :289-294

[2] Stereotactic radiosurgery for vestibular schwannomas in patients with neurofibromatosis type 2: An analysis of tumor control, complications, and hearing preservation rates [J].

Mathieu, David ;

Kondziolka, Douglas ;

Flickinger, John C. ;

Niranjan, Ajay ;

Williamson, Richard ;

Martin, Juan J. ;

Dade Lunsford, L. .

NEUROSURGERY, 2007, 60 (03) :460-468

[3] The neuroimaging and clinical spectrum of neurofibromatosis 2 [J].

Mautner, VF ;

Lindenau, M ;

Baser, ME ;

Hazim, W ;

Tatagiba, M ;

Haase, W ;

Samii, M ;

Wais, R ;

Pulst, SM .

NEUROSURGERY, 1996, 38 (05) :880-885

[4] Bevacizumab for recurrent malignant gliomas - Efficacy, toxicity, and patterns of recurrence [J].

Norden, A. D. ;

Young, G. S. ;

Setayesh, K. ;

Muzikansky, A. ;

Klufas, R. ;

Ross, G. L. ;

Ciampa, A. S. ;

Ebbeling, L. G. ;

Levy, B. ;

Drappatz, J. ;

Kesari, S. ;

Wen, P. Y. .

NEUROLOGY, 2008, 70 (10) :779-787

[5] Multichannel auditory brainstem implant: update on performance in 61 patients [J].

Otto, SR ;

Brackmann, DE ;

Hitselberger, WE ;

Shannon, RV ;

Kuchta, J .

JOURNAL OF NEUROSURGERY, 2002, 96 (06) :1063-1071

[6] Audiologic and radiographic response of NF2-related vestibular schwannoma to erlotinib therapy [J].

Plotkin, Scott R. ;

Singh, Marybeth A. ;

O'Donnell, Caroline C. ;

Harris, Gordon J. ;

McClatchey, Andrea I. ;

Halpin, Chris .

NATURE CLINICAL PRACTICE ONCOLOGY, 2008, 5 (08) :487-491

[7] Expression of VEGF and its receptor genes in intracranial schwannomas [J].

Uesaka, Toshio ;

Shono, Tadahisa ;

Suzuki, Satoshi O. ;

Nakamizo, Akira ;

Niiro, Hiroaki ;

Mizoguchi, Masahiro ;

Iwaki, Toru ;

Sasaki, Tomio .

JOURNAL OF NEURO-ONCOLOGY, 2007, 83 (03) :259-266

[8] Taming glioblastoma: Targeting angiogenesis [J].

Wong, Eric T. ;

Brem, Steven .

JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (30) :4705-4706

[9] Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan [J].

Zuniga, R. M. ;

Torcuator, R. ;

Jain, R. ;

Anderson, J. ;

Doyle, T. ;

Ellika, S. ;

Schultz, L. ;

Mikkelsen, T. .

JOURNAL OF NEURO-ONCOLOGY, 2009, 91 (03) :329-336

← 1 →